Abstract:Background The UGT1A1*28 polymorphism, although closely linked with CPT-11-related adverse effects, cannot be used alone to guide individualized treatment decisions. However, CPT-11 dosage can be adjusted according to measured SN-38 pharmacokinetics. Our study is designed to investigate whether there is a relationship between SN-38 peak or valley concentrations and efficacy or adverse effects of CPT-11-based chemotherapy. We retrospectively studied 98 patients treated with advanced colorectal cancer in various UGT1A1*28 genotype groups (mainly (TA) 6 /(TA) 6 and (TA) 6 /(TA) 7 genotypes) treated with CPT-11 as first-line chemotherapy in Shanghai. Methods One hundred and sixty-four advanced colorectal cancer patients were enrolled. To understand differences in genotype expression, the frequency of UGT1A1*28 thymine–adenine (TA) repeats in TATA box arrangement was assessed by PCR with genomic DNA extracted from peripheral blood. For ninety-eight cases with the (TA) 6 /(TA) 6 and (TA) 6 /(TA) 7 genotypes treated with CPT-11 as first-line chemotherapy, the plasma concentration of SN-38 was detected by HPLC 1.5 and 49 h after CPT-11 infusion. Efficacy and adverse effects were observed subsequently, and the relationship between SN-38 plasma concentration and efficacy or adverse effects within genotype groups, as well as differences in efficacy and adverse effects between (TA) 6 /(TA) 6 and (TA) 6 /(TA) 7 genotypes were analyzed statistically. Results One hundred and fourteen patients (69.51 %) were identified with the (TA) 6 /(TA) 6 genotype, forty-eight patients (29.27 %) with the (TA) 6 /(TA) 7 genotype, and two patients (1.22 %) with the (TA) 7 /(TA) 7 genotype. The average peak and valley concentrations of SN-38 after CPT-11 infusion and plasma bilirubin average levels before and after CPT-11 treatment in the (TA) 6 /(TA) 7 genotype group were all higher than those in (TA) 6 /(TA) 6 group, and the difference was statistically significant ( p = 0.00). Stepwise regression analysis showed that SN-38 peak and valley concentration was correlated with PFS in the (TA) 6 /(TA) 6 genotype. In the (TA) 6 /(TA) 7 group, SN-38 peak concentration was correlated with CPT-11 starting dose and OS, valley concentration correlated with plasma bilirubin levels before CPT-11 treatment, delayed diarrhea, and OS. For the (TA) 6 /(TA) 6 genotype, mPFS of the SN-38 peak concentration >43.2 ng/ml subgroup was significantly longer than that of ≤43.2 ng/ml subgroup (8.0 ± 0.35 vs. 6.5 ± 0.79 months, χ 2 = 17.18, p = 0.00) with a relatively high incidence of Grade I/II° myelosuppression; for the (TA) 6 /(TA) 7 genotype, there was no significant difference in mOS between the SN-38 valley concentration >16.83 ng/ml and ≤16.83 subgroups (17.3 ± 0.45 vs. 18.8 ± 0.50 months, χ 2 = 1.38, p = 0.24), but the former had a higher incidence of Grade III/IV° mucositis and delayed diarrhea. For 2 (TA) 7 /(TA) 7 cases, although 25 % dose reduction of CPT-11, which is calculated according to body surface area, Grade IV° bone marrow suppression and Grade III° delayed diarrhea still occurred after CPT-11 treatment, though both adverse effects resolved and did not recur again after a 50 % dose reduction. Conclusion The (TA) 6 /(TA) 6 genotype and (TA) 6 /(TA) 7 genotype accounted for the most, and (TA) 7 /(TA) 7 genotype only account for a very small portion of advanced colorectal cancer patients in Shanghai. For the (TA) 6 /(TA) 6 genotype, CPT-11 dosage can be increased gradually to improve efficacy for patients with SN-38 peak concentration ≤43.2 ng/ml after CPT-11 infusion; and for (TA) 6 /(TA) 7 genotype patients, CPT-11 dosage may be lowered appropriately to reduce serious adverse effects such as bone marrow suppression and delayed diarrhea without affecting the efficacy for those with SN-38 valley concentration >16.83 ng/ml. For (TA) 7 /(TA) 7 genotype patients, adverse effects should be closely observed after treatment even if CPT-11 dosage has been reduced.

Rapid detection of the irinotecan‐related UGT1A1*28 polymorphism by asymmetric PCR melting curve analysis using one fluorescent probe

Rapid detection of the irinotecan-related UGT1A1 & 5-fluorouracil related DPYD polymorphism by asymmetric polymerase chain reaction melting curve analysis

[Polymorphisms of UGT1A Gene and Irinotecan Toxicity in Chinese Colorectal Cancer Patients].

UGT1A1 Predicts Outcome in Colorectal Cancer Treated with Irinotecan and Fluorouracil.

UGT1A1*28 detection using high-resolution agarose gel electrophoresis

An extraction‐free method for rapid detection of CYP2C19 * 2/3/17 polymorphisms in one tube using melting curve analysis

Relationship between UGT1A16/28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy.

Relationship between UGT1A1 gene polymorphisms and toxicity of irinotecan-based chemotherapy ;in colorectal cancer

Predictive Value of UGT1A1*28 Polymorphism in Irinotecan-based Chemotherapy

A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients

Clinical Study of the Correlation between UGT1A1 Polymorphism and the Safety and Efficacy of Irinotecan

UGT1A1 6/28 Polymorphisms Could Predict Irinotecan-Induced Severe Neutropenia Not Diarrhea in Chinese Colorectal Cancer Patients.

An Oligonucleotide Microarray for Detection of Cytochrome P450 Enzyme Gene Polymorphisms Related to Paclitaxel Metabolism

Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai

Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.

Rapid Allele-Specific PCR method for CDA 79A>C (K27Q) genotyping: A useful pharmacogenetic tool and world-wide polymorphism distribution

A study on the relationship between the adverse events of irinotecan-based chemotherapy and UGT1A1*28 gene polymorphism

Oligonucleotide Microarray: A New Rapid Method for Screening the 23S Rrna Gene of Helicobacter Pylori for Single Nucleotide Polymorphisms Associated with Clarithromycin Resistance

Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations

Establishment and verification of TaqMan-MGB two-color fluorescent probe method for detecting the gene polymorphisms of insulin receptor substrate 1 rs1801278

UGT1A1 Genotype-Guided Irinotecan Dosing During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Prospective Analysis of SN-38 Concentration